Skip to main content

CORRECTION article

Front. Cardiovasc. Med., 18 February 2022
Sec. Cardiovascular Epidemiology and Prevention
Volume 9 - 2022 | https://doi.org/10.3389/fcvm.2022.844270

Corrigendum: Rationale and Design of a Pharmacist-led Intervention for the Risk-Based Prevention of Heart Failure: The FIT-HF Pilot Study

This article is a correction to:

  1. Rationale and Design of a Pharmacist-led Intervention for the Risk-Based Prevention of Heart Failure: The FIT-HF Pilot Study

    1. Read original article
\nMichael C. WangMichael C. Wang1Bridget DolanBridget Dolan2Benjamin H. FreedBenjamin H. Freed3Lourdes VegaLourdes Vega2Nikola MarkoskiNikola Markoski2Amy E. WainrightAmy E. Wainright2Bonnie KaneBonnie Kane1Laura E. SeegmillerLaura E. Seegmiller1Katharine HarringtonKatharine Harrington1Alana A. LewisAlana A. Lewis3Sanjiv J. Shah,Sanjiv J. Shah1,3Clyde W. YancyClyde W. Yancy3Ian J. Neeland,Ian J. Neeland4,5Hongyan NingHongyan Ning1Donald M. Lloyd-Jones,Donald M. Lloyd-Jones1,3Sadiya S. Khan, Sadiya S. Khan1,3*
  • 1Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, United States
  • 2Department of Pharmacy, Northwestern Memorial Hospital, Chicago, IL, United States
  • 3Division of Cardiology, Northwestern University Feinberg School of Medicine, Chicago, IL, United States
  • 4Department of Medicine, University Hospitals Cleveland Medical Center, Cleveland, OH, United States
  • 5Case Western Reserve University School of Medicine, Cleveland, OH, United States

A Corrigendum on
Rationale and Design of a Pharmacist-led Intervention for the Risk-Based Prevention of Heart Failure: The FIT-HF Pilot Study

by Wang, M. C., Dolan, B., Freed, B. H., Vega, L., Markoski, N., Wainright, A. E., Kane, B., Seegmiller, L. E., Harrington, K., Lewis, A. A., Shah, S. J., Yancy, C. W., Neeland, I. J., Ning, H., Lloyd-Jones, D. M., and Khan, S. S. (2021). Front. Cardiovasc. Med. 8:785109. doi: 10.3389/fcvm.2021.785109

In the original article, there was a mistake in Figure 2 (Pharmacist-directed intervention treatment algorithm) as published. The decision tree boxes “African American OR ACE inh intolerant” and “Not African American AND ACE inh tolerant” were reversed, and the abbreviation “ACE inh” instead of “ACEi” was used. The corrected Figure 2 (Pharmacist-directed intervention treatment algorithm) appears below.

FIGURE 2
www.frontiersin.org

Figure 2. Pharmacist-directed intervention treatment algorithm. The treatment algorithm was derived from professional society guidelines for the primary prevention of cardiovascular disease as well as blood pressure, glucose, and lipid lowering. Special consideration is given to the early initiation of SGLT-2 inhibitors in patients with diabetes, given the evidence supporting their efficacy in heart failure prevention and current guideline recommendations. BP represents blood pressure; ACEi angiotensin converting enzyme inhibitor; ARB angiotensin receptor blocker; CCB calcium channel blocker; SMBG self-monitored blood glucose; eGFR estimated glomerular filtration rate; PCP primary care physician; DM diabetes mellitus; SBP systolic blood pressure; DBP diastolic blood pressure; HTN hypertension.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: heart failure, primary prevention, pharmacist, risk prediction, natriuretic peptides

Citation: Wang MC, Dolan B, Freed BH, Vega L, Markoski N, Wainright AE, Kane B, Seegmiller LE, Harrington K, Lewis AA, Shah SJ, Yancy CW, Neeland IJ, Ning H, Lloyd-Jones DM and Khan SS (2022) Corrigendum: Rationale and Design of a Pharmacist-led Intervention for the Risk-Based Prevention of Heart Failure: The FIT-HF Pilot Study. Front. Cardiovasc. Med. 9:844270. doi: 10.3389/fcvm.2022.844270

Received: 27 December 2021; Accepted: 28 January 2022;
Published: 18 February 2022.

Edited and reviewed by: Paolo Emilio Puddu, Université de Caen Normandie, France

Copyright © 2022 Wang, Dolan, Freed, Vega, Markoski, Wainright, Kane, Seegmiller, Harrington, Lewis, Shah, Yancy, Neeland, Ning, Lloyd-Jones and Khan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Sadiya S. Khan, cy1raGFuLTEmI3gwMDA0MDtub3J0aHdlc3Rlcm4uZWR1

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.